Atlanta, GA – VasoCorp, makers of NeuropAWAY® announced that it will soon release its new “Pre-D® Formula™” to combat prediabetes and address the complications of early nerve damage caused by impaired glucose tolerance. Research shows that 40% of patients diagnosed with impaired glucose tolerance (prediabetes) have evidence of significant nerve damage. The CDC estimates that the number of people in the United States with prediabetes to be around 94M and growing at alarming rates. William Cross, VasoCorp’s CEO said that “VasoCorp will continue to focus their research on products aimed at helping those with diabetes, prediabetes and other autoimmune diseases.”
Prediabetes is a serious health condition where blood sugar levels are higher than normal, but not high enough yet to be diagnosed as diabetes. Prediabetes puts people at increased risk of developing type 2 diabetes, neuropathy, heart disease, and stroke. VasoCorp hopes to help prevent these early complications by targeting them with its new “Pre-D® Formula™.”
